Synimmune GmbH is a biotechnology company dedicated to the development of innovative and effective mono- and bispecific antibodies for the treatment of life-threatening diseases. With a particular focus on orphan hematopoietic malignancies, Synimmune aims to improve immunotherapy through the development of novel antibody therapies. Their lead product candidate, FLYSYN, is currently undergoing a first-in-human phase I clinical study in acute myeloid leukemia (AML).

Synimmune GmbH is a spin-off of the Department of Immunology at the University of Tuebingen and is supported by grants from the German Ministry of Education and Research (BMBF) and investments by the German KfW and private equity. As a testament to their commitment to excellence, Synimmune has recently signed a manufacturing service agreement with GenScript ProBio, a highly professional and competent CDMO (Contract Development and Manufacturing Organization). For AML patients interested in participating in their clinical study, more information can be found on their website.

Synimmune GmbH is a pioneering brand at the forefront of developing innovative immunotherapeutic solutions to address challenging medical conditions